PMID- 12833656
OWN - NLM
STAT- MEDLINE
DCOM- 20030908
LR  - 20161124
IS  - 1472-4472 (Print)
IS  - 1472-4472 (Linking)
VI  - 4
IP  - 5
DP  - 2003 May
TI  - BMS-561392. Bristol-Myers Squibb.
PG  - 598-602
AB  - Bristol-Myers Squibb Pharma Co is developing the tumor necrosis factor-alpha (TNF 
      alpha) converting enzyme inhibitor BMS-561392 (DPC-333) for the potential 
      treatment of diseases characterized by overproduction of TNF alpha, such as 
      rheumatoid arthritis (RA). A phase IIa trial in RA patients had commenced by 
      April 2001, and by October 2002, BMS-561392 was also under investigation for the 
      potential treatment of inflammatory bowel disease.
FAU - Grootveld, Martin
AU  - Grootveld M
AD  - Department of Diabetes and Metabolic Medicine, Queen Mary, University of London, 
      Mile End Road, London E1 1BB, UK.
FAU - McDermott, Michael F
AU  - McDermott MF
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Investig Drugs
JT  - Current opinion in investigational drugs (London, England : 2000)
JID - 100965718
RN  - 0 (BMS561392)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Quinolines)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 3.4.24.- (ADAM Proteins)
RN  - EC 3.4.24.- (Metalloendopeptidases)
RN  - EC 3.4.24.86 (ADAM17 Protein)
SB  - IM
MH  - ADAM Proteins
MH  - ADAM17 Protein
MH  - Animals
MH  - Arthritis, Rheumatoid/drug therapy/enzymology
MH  - Enzyme Inhibitors/chemistry/pharmacology/*therapeutic use
MH  - Humans
MH  - Inflammatory Bowel Diseases/drug therapy/enzymology
MH  - Metalloendopeptidases/*antagonists & inhibitors/metabolism
MH  - Quinolines/chemistry/pharmacology/*therapeutic use
MH  - Technology, Pharmaceutical/*methods
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
RF  - 26
EDAT- 2003/07/02 05:00
MHDA- 2003/09/10 05:00
CRDT- 2003/07/02 05:00
PHST- 2003/07/02 05:00 [pubmed]
PHST- 2003/09/10 05:00 [medline]
PHST- 2003/07/02 05:00 [entrez]
PST - ppublish
SO  - Curr Opin Investig Drugs. 2003 May;4(5):598-602.